What is it used for?
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- imetelstatimetelstat
- Form and strength
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 47 mg; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 188 mgINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 47 mg; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 188 mg
- Manufacturer / applicant
- GERON CORPORATIONGERON CORPORATION
For injection: 47 mg of imetelstat supplied as a white to off-white or slightly yellow lyophilized powder in a single-dose vial for reconstitution. For injection: 188 mg of imetelstat supplied as a white to off-white or slightly yellow …For injection: 47 mg of imetelstat supplied as a white to off-white or slightly yellow lyophilized powder in a single-dose vial for reconstitution. For injection: 188 mg of imetelstat supplied as a white to off-white or slightly yellow …
Safety and clinical review
- ThrombocytopeniaThrombocytopenia
- NeutropeniaNeutropenia
- Infusion-Related ReactionsInfusion-Related Reactions
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Rytelo used for?
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Rytelo should I ask about?
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 47 mg; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 188 mgINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 47 mg; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 188 mg
Read the primary sourceWhat determines the price of Rytelo?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Rytelo?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.